Trials / Not Yet Recruiting
Not Yet RecruitingNCT07309913
China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort)
China Atrial Fibrillation With Complex Metabolic Disorders Cohort Study (CAME Cohort)
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,459 (estimated)
- Sponsor
- Xiangya Hospital of Central South University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The number of atrial fibrillation (AF) patients in China is approximately 32.76 million, with a prevalence rate of 2.3%. AF is associated with severe outcomes such as stroke and heart failure. Metabolic disorders (e.g., obesity, diabetes mellitus, dyslipidemia) are closely linked to the onset and prognosis of AF. However, the epidemiological characteristics and disease burden of AF combined with metabolic disorders in China remain unclear. Additionally, the impact of complex multi-dimensional metabolic disorders on AF prognosis requires further investigation, and current clinical guidelines lack targeted management recommendations for this population.
Conditions
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2036-02-01
- Completion
- 2036-06-01
- First posted
- 2025-12-30
- Last updated
- 2025-12-30
Source: ClinicalTrials.gov record NCT07309913. Inclusion in this directory is not an endorsement.